Ubiquitin	B-GP
E3	I-GP
ligase	I-GP
MARCH7	B-GP
promotes	O
ovarian	B-DS
tumor	I-DS
growth	O

Ubiquitin	B-GP
E3	I-GP
ligase	I-GP
MARCH7	B-GP
is	O
involved	O
in	O
T	O
cell	O
proliferation	O
and	O
neuronal	O
development	O
.	O

We	O
found	O
that	O
expression	O
of	O
MARCH7	B-GP
was	O
higher	O
in	O
ovarian	B-DS
cancer	I-DS
tissues	O
than	O
normal	O
ovarian	O
tissues	O
.	O

Silencing	O
MARCH7	B-GP
decreased	O
cell	O
proliferation	O
,	O
migration	O
,	O
and	O
invasion	O
.	O

Ectopic	O
expression	O
of	O
MARCH7	B-GP
increased	O
cell	O
proliferation	O
,	O
migration	O
and	O
invasion	O
.	O

Silencing	O
MARCH7	B-GP
prevented	O
ovarian	B-DS
cancer	I-DS
growth	O
in	O
mice	B-OG
.	O

Silencing	O
MARCH7	B-GP
inhibited	O
NFkB	B-GP
and	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
pathway	O
.	O

In	O
agreement	O
,	O
ectopically	O
expressed	O
MARCH7	B-GP
activated	O
NFkB	B-GP
and	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
pathways	O
.	O

Finally	O
,	O
MARCH7	B-GP
was	O
regulated	O
by	O
miR	O
-	O
101	O
.	O

Thus	O
,	O
MARCH7	B-GP
is	O
oncogenic	O
and	O
a	O
potential	O
target	O
(	O
oncotarget	O
)	O
for	O
ovarian	B-DS
cancer	I-DS
therapy	O
.	O

INTRODUCTION	O

The	O
membrane	B-GP
-	I-GP
associated	I-GP
RING	I-GP
-	I-GP
CH	I-GP
(	O
MARCH	B-GP
)	O
proteins	O
belong	O
to	O
the	O
RING	B-GP
finger	I-GP
protein	I-GP
family	O
of	O
E3	B-GP
ubiquitin	I-GP
ligases	I-GP
,	O
consisting	O
of	O
11	O
members	O
in	O
mammals	B-OG
.	O

MARCH	B-GP
proteins	O
have	O
numerous	O
cellular	O
functions	O
,	O
which	O
include	O
immune	O
regulation	O
,	O
protein	O
quality	O
control	O
,	O
membrane	O
trafficking	O
,	O
and	O
spermatogenesis	O
[	O
1	O
].	O

MARCH7	B-GP
is	O
a	O
member	O
of	O
the	O
MARCH	B-GP
family	O
,	O
which	O
consists	O
of	O
approximately	O
690	O
amino	O
acids	O
within	O
a	O
single	O
RING	O
finger	O
domain	O
[	O
2	O
].	O

Previous	O
studies	O
have	O
suggested	O
that	O
MARCH7	B-GP
plays	O
an	O
important	O
role	O
in	O
T	O
cell	O
proliferation	O
and	O
neuronal	O
development	O
[	O
3	O
].	O

MARCH7	B-GP
is	O
expressed	O
in	O
multiple	O
types	O
of	O
cells	O
and	O
tissues	O
,	O
including	O
stem	O
cells	O
and	O
precursor	O
cells	O
[	O
4	O
],	O
suggesting	O
its	O
possible	O
role	O
in	O
cell	O
and	O
tissue	O
differentiation	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
cellular	O
localization	O
and	O
function	O
of	O
MARCH7	B-GP
in	O
ovarian	B-DS
carcinoma	I-DS
.	O

In	O
this	O
study	O
,	O
we	O
have	O
observed	O
an	O
aberrant	O
expression	O
and	O
localization	O
of	O
MARCH7	B-GP
in	O
ovarian	B-DS
cancer	I-DS
tissues	O
by	O
immunohistochemical	O
analyses	O
.	O

Additionally	O
,	O
we	O
have	O
elucidated	O
the	O
functions	O
of	O
MARCH7	B-GP
in	O
ovarian	B-DS
cancer	I-DS
.	O

Our	O
results	O
show	O
that	O
MARCH7	B-GP
participates	O
in	O
the	O
regulation	O
of	O
cytoskeleton	O
re	O
-	O
organization	O
,	O
cellular	O
migration	O
and	O
invasion	O
,	O
cell	O
proliferation	O
,	O
and	O
tumorigenesis	O
in	O
ovarian	B-DS
carcinoma	I-DS
cells	O
.	O

At	O
the	O
same	O
time	O
,	O
we	O
found	O
that	O
MARCH	B-GP
7	O
could	O
modulate	O
nuclear	B-GP
factor	I-GP
kB	I-GP
(	O
NF	B-GP
-	I-GP
kB	I-GP
)	O
and	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
pathways	O
.	O

Further	O
,	O
we	O
identified	O
MARCH7	B-GP
was	O
an	O
authentic	O
target	O
of	O
miR	O
-	O
101	O
.	O

RESULTS	O

Aberrant	O
expression	O
of	O
MARCH7	B-GP
in	O
ovarian	B-DS
carcinoma	I-DS
tissues	O

The	O
expression	O
profile	O
of	O
MARCH	B-GP
7	O
in	O
ovarian	B-DS
cancer	I-DS
is	O
not	O
yet	O
fully	O
elucidated	O
.	O

We	O
examined	O
the	O
expression	O
pattern	O
of	O
MARCH7	B-GP
in	O
normal	O
ovary	O
and	O
ovarian	B-DS
cancer	I-DS
tissue	O
samples	O
using	O
IHC	O
.	O

The	O
expression	O
of	O
MARCH7	B-GP
was	O
significantly	O
higher	O
in	O
ovarian	B-DS
carcinoma	I-DS
samples	O
than	O
that	O
in	O
normal	O
ovarian	O
samples	O
(	O
Fig	O
.	O
1	O
and	O
Table	O
1	O
).	O

MARCH7	B-GP
was	O
predominantly	O
localized	O
on	O
the	O
plasma	O
membrane	O
,	O
and	O
cytoplasm	O
(	O
Fig	O
.	O
1A	O
-	O
H	O
).	O

MARCH7	B-GP
expression	O
was	O
significantly	O
higher	O
in	O
epithelial	B-DS
ovarian	I-DS
cancer	I-DS
samples	O
than	O
that	O
in	O
normal	O
ovary	O
tissues	O
(	O
P	O
<	O
0	O
.	O
05	O
;	O
Table	O
1	O
).	O

To	O
determine	O
the	O
correlation	O
of	O
MARCH7	B-GP
expression	O
with	O
cancer	B-DS
type	O
and	O
cancer	B-DS
stage	O
,	O
all	O
cancer	B-DS
samples	O
were	O
grouped	O
into	O
histologic	O
types	O
(	O
serous	B-DS
papillary	I-DS
adenocarcinoma	I-DS
,	O
mucinous	B-DS
adenocarcinoma	I-DS
,	O
and	O
endometrioid	B-DS
adenocarcinoma	I-DS
)	O
(	O
Fig	O
.	O
1A	O
-	O
H	O
).	O

The	O
differently	O
expression	O
of	O
MARCH7	B-GP
between	O
serous	B-DS
adenocarcinoma	I-DS
and	O
other	O
histologic	O
type	O
of	O
the	O
tumor	B-DS
was	O
not	O
significant	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

MARCH7	B-GP
immunostaining	O
was	O
significantly	O
higher	O
in	O
tumor	B-DS
samples	O
in	O
advanced	O
stages	O
(	O
stage	O
III	O
/	O
IV	O
)	O
as	O
compared	O
to	O
those	O
in	O
the	O
early	O
stages	O
(	O
stage	O
I	O
/	O
II	O
)	O
disease	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Further	O
,	O
the	O
staining	O
intensity	O
significantly	O
correlated	O
with	O
the	O
tumor	B-DS
grade	O
(	O
grades	O
2	O
–	O
3	O
versus	O
1	O
,	O
P	O
<	O
0	O
.	O
01	O
).	O

However	O
,	O
the	O
associations	O
between	O
MARCH7	B-GP
expression	O
and	O
age	O
were	O
not	O
significant	O
(	O
P	O
>	O
0	O
.	O
05	O
;	O
Table	O
1	O
).	O

Association	O
of	O
MARCH7	B-GP
expression	O
with	O
clinicopathological	O
characteristics	O
in	O
158	O
patients	O
of	O
EOC	B-DS

No	O
.	O
of	O
patients	O

MARCH7	B-GP
expression	O

P	O
value	O

(	O
n	O
=	O
158	O
)	O

Low	O
no	O
.(%)	O

High	O
no	O
.(%)	O

Characteristics	O

Age	O
(	O
years	O
)	O

>	O
0	O
.	O
5	O

<	O
50	O

83	O

36	O
(	O
43	O
.	O
37	O
%)	O

47	O
(	O
56	O
.	O
63	O
%)	O

≥	O
50	O

75	O

35	O
(	O
46	O
.	O
67	O
%)	O

40	O
(	O
53	O
.	O
33	O
%)	O

Normal	O
ovarian	O

20	O

18	O
(	O
90	O
%)	O

2	O
(	O
10	O
%)	O

<	O
0	O
.	O
05	O

Cancer	B-DS
tissues	O

138	O

79	O
(	O
57	O
.	O
25	O
)	O

59	O
(	O
42	O
.	O
75	O
%)	O

FIGO	O
stage	O

I	O
/	O
II	O

103	O

74	O
(	O
71	O
.	O
84	O
%)	O

29	O
(	O
28	O
.	O
16	O
%)	O

<	O
0	O
.	O
001	O

III	O
/	O
IV	O

35	O

5	O
(	O
14	O
.	O
29	O
%)	O

30	O
(	O
85	O
.	O
71	O
%)	O

Grade	O

1	O

30	O

23	O
(	O
76	O
.	O
67	O
%)	O

7	O
(	O
23	O
.	O
33	O
%)	O

2	O

36	O

24	O
(	O
66	O
.	O
67	O
%)	O

12	O
(	O
33	O
.	O
33	O
%)	O

3	O

72	O

30	O
(	O
41	O
.	O
67	O
%)	O

42	O
(	O
58	O
.	O
33	O
%)	O

Grade	O
2	O
-	O
3	O
versus	O
1	O

<	O
0	O
.	O
05	O

Tumor	B-DS
type	O

Serous	O

120	O

67	O
(	O
32	O
.	O
81	O
%)	O

53	O
(	O
67	O
.	O
19	O
%)	O

Mucinous	O

14	O

11	O
(	O
81	O
.	O
25	O
%)	O

3	O
(	O
18	O
.	O
75	O
%)	O

Endometrioid	O

4	O

1	O
(	O
75	O
%)	O

3	O
(	O
25	O
%)	O

Serous	O
versus	O
non	O
-	O
serous	O

>	O
0	O
.	O
005	O

Immunohistochemical	O
analysis	O
of	O
MARCH7	B-GP
expression	O
in	O
ovarian	B-DS
cancer	I-DS

MARCH7	B-GP
was	O
predominantly	O
localized	O
in	O
the	O
(	O
A	O
)	O
plasma	O
membrane	O
,	O
(	O
B	O
,	O
C	O
,	O
D	O
,	O
E	O
)	O
cytoplasm	O
.	O

The	O
expression	O
of	O
MARCH7	B-GP
in	O
different	O
types	O
of	O
ovarian	B-DS
cancer	I-DS
samples	O
.	O

(	O
A	O
).	O
serous	B-DS
papillary	I-DS
adenocarcinoma	I-DS
(	O
stage	O
I	O
);	O
(	O
B	O
).	O
serous	B-DS
papillary	I-DS
adenocarcinoma	I-DS
(	O
stage	O
IIIA	O
);	O
(	O
C	O
).	O
serous	B-DS
papillary	I-DS
adenocarcinoma	I-DS
(	O
stage	O
IIIC	O
);	O
(	O
D	O
).	O
mucinous	B-DS
adenocarcinoma	I-DS
mucinous	B-DS
adenocarcinoma	I-DS
(	O
stage	O
IA	O
);	O
(	O
E	O
).	O
mucinous	B-DS
adenocarcinoma	I-DS
mucinous	B-DS
adenocarcinoma	I-DS
(	O
stage	O
IB	O
)	O
;	O
(	O
F	O
).	O
mucinous	B-DS
adenocarcinoma	I-DS
mucinous	B-DS
adenocarcinoma	I-DS
(	O
stage	O
III	O
);	O
(	O
G	O
).	O
endometrioid	B-DS
adenocarcinoma	I-DS
(	O
stage	O
I	O
);	O
(	O
H	O
).	O
endometrioid	B-DS
adenocarcinoma	I-DS
(	O
stage	O
III	O
);	O
(	O
I	O
).	O
normal	O
ovarian	O
tissue	O
.	O

Original	O
magnification	O
,	O
200X	O
.	O

MARCH7	B-GP
expression	O
in	O
ovarian	B-DS
cancer	I-DS
cell	O
lines	O

The	O
expression	O
of	O
MARCH7	B-GP
was	O
investigated	O
in	O
7	O
cell	O
lines	O
at	O
the	O
mRNA	O
level	O
by	O
real	O
-	O
time	O
quantitative	O
PCR	O
(	O
qPCR	O
)	O
to	O
select	O
suitable	O
cell	O
lines	O
for	O
functional	O
assays	O
.	O

Of	O
these	O
,	O
MARCH7	B-GP
expression	O
was	O
higher	O
in	O
the	O
SKOV3	O
,	O
CaOV	O
-	O
3	O
,	O
and	O
Es	O
-	O
2	O
cell	O
lines	O
,	O
than	O
in	O
the	O
A2780	O
cell	O
line	O
(	O
Fig	O
.	O
2A	O
).	O

Therefore	O
,	O
A2780	O
cell	O
line	O
was	O
selected	O
for	O
exogenous	O
expression	O
;	O
SKOV3	O
cell	O
was	O
selected	O
for	O
down	O
-	O
regulation	O
of	O
MARCH7	B-GP
to	O
determine	O
the	O
MARCH7	B-GP
functions	O
.	O

The	O
mRNA	O
and	O
protein	O
level	O
of	O
MARCH7	B-GP
was	O
decreased	O
in	O
LV3	O
-	O
shMARCH7	O
-	O
1	O
or	O
LV3	O
-	O
shMARCH7	O
-	O
2	O
infected	O
SKOV3	O
cells	O
compared	O
with	O
LV3	O
-	O
NC	O
SKOV3	O
cells	O
(	O
Fig	O
.	O
2B	O
and	O
2C	O
).	O

MARCH7	B-GP
regulates	O
cellular	O
proliferation	O

Our	O
data	O
showed	O
that	O
downregulation	O
of	O
MARCH7	B-GP
using	O
LV3	O
-	O
shMARCH7	O
-	O
1	O
and	O
LV3	O
-	O
shMARCH7	O
-	O
2	O
could	O
inhibit	O
cell	O
proliferation	O
in	O
ovarian	B-DS
cancer	I-DS
SKOV3	O
cell	O
(	O
P	O
<	O
0	O
.	O
05	O
;	O
Fig	O
.	O
2D	O
,	O
2E	O
and	O
2F	O
).	O

The	O
efficiency	O
of	O
colony	O
formation	O
had	O
decreased	O
in	O
LV3	O
-	O
shMARCH7	O
-	O
1	O
or	O
LV3	O
-	O
shMARCH7	O
-	O
2	O
infected	O
SKOV3	O
cells	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
(	O
Fig	O
.	O
2G	O
and	O
2H	O
).	O

On	O
the	O
other	O
hand	O
,	O
we	O
investigated	O
the	O
overexpression	O
of	O
MARCH7	B-GP
in	O
A2780	O
cell	O
by	O
exposing	O
them	O
to	O
LV5	O
-	O
MARCH7	B-GP
.	O

Our	O
data	O
showed	O
that	O
overexpression	O
of	O
MARCH7	B-GP
in	O
A2780	O
cells	O
resulted	O
in	O
an	O
increase	O
in	O
cell	O
proliferation	O
compared	O
to	O
LV	O
-	O
5	O
-	O
GFP	B-GP
-	O
exposed	O
cells	O
(	O
P	O
<	O
0	O
.	O
05	O
;	O
Fig	O
.	O
2I	O
,	O
2J	O
and	O
2K	O
).	O

This	O
was	O
consistent	O
with	O
the	O
exogenous	O
expression	O
of	O
MARCH7	B-GP
that	O
increased	O
the	O
colony	O
forming	O
capacity	O
in	O
contrast	O
with	O
LV	O
-	O
5	O
-	O
GFP	B-GP
infected	O
cells	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
(	O
Fig	O
.	O
2L	O
and	O
2M	O
).	O

However	O
,	O
MARCH7	B-GP
knockdown	O
did	O
not	O
induce	O
cell	O
apoptosis	O
(	O
data	O
not	O
presented	O
).	O

MARCH7	B-GP
regulated	O
the	O
proliferation	O
of	O
ovarian	B-DS
cancer	I-DS
SKOV3	O
and	O
A2780	O
cells	O

(	O
A	O
)	O
The	O
relative	O
expression	O
of	O
MARCH7	B-GP
mRNA	O
in	O
ovarian	B-DS
cancer	I-DS
cell	O
lines	O
.	O

(	O
B	O
,	O
C	O
)	O
MARCH7	B-GP
mRNA	O
and	O
protein	O
level	O
were	O
down	O
-	O
regulated	O
by	O
infected	O
with	O
LV3	O
-	O
shMARCH7	O
-	O
1	O
or	O
LV3	O
-	O
shMARCH7	O
-	O
2	O
.	O

(	O
D	O
,	O
E	O
)	O
Ovarian	B-DS
cancer	I-DS
SKOV3	O
cells	O
were	O
infected	O
with	O
LV3	O
-	O
NC	O
,	O
LV3	O
-	O
shMARCH7	O
-	O
1	O
and	O
LV3	O
-	O
shMARCH7	O
-	O
2	O
.	O

Cell	O
proliferation	O
was	O
assessed	O
by	O
EdU	O
.	O

The	O
proliferation	O
rate	O
of	O
LV3	O
-	O
shMARCH7	O
-	O
1	O
and	O
LV3	O
-	O
shMARCH7	O
-	O
2	O
cells	O
was	O
lower	O
than	O
that	O
of	O
LV3	O
-	O
NC	O
cells	O
.	O

Original	O
magnification	O
,	O
200X	O
.	O

(	O
F	O
)	O
Cell	O
proliferation	O
was	O
determined	O
by	O
CCK	O
-	O
8	O
assay	O
.	O

(	O
G	O
,	O
H	O
)	O
Colony	O
formation	O
assay	O
.	O

Skov3	O
cells	O
infected	O
with	O
Lv3	O
-	O
shMarch7	O
-	O
1	O
or	O
Lv3	O
-	O
shMarch7	O
-	O
2	O
were	O
cultured	O
by	O
seeding	O
1	O
,	O
000	O
cells	O
in	O
6	O
-	O
well	O
plates	O
and	O
enumerating	O
the	O
number	O
of	O
colonies	O
formed	O
in	O
2	O
weeks	O
.	O

The	O
number	O
of	O
colony	O
formation	O
of	O
LV3	O
-	O
shMARCH7	O
-	O
1	O
or	O
LV3	O
-	O
shMARCH7	O
-	O
2	O
was	O
lower	O
as	O
compared	O
with	O
LV3	O
-	O
NC	O
.	O

(	O
I	O
,	O
J	O
)	O
Ovarian	B-DS
cancer	I-DS
A2780	O
cells	O
were	O
infected	O
with	O
LV5	O
-	O
GFP	B-GP
or	O
LV5	O
-	O
MARCH7	B-GP
.	O

Then	O
cell	O
proliferation	O
was	O
determined	O
by	O
EdU	O
.	O

Original	O
magnification	O
,	O
200X	O
.	O

The	O
proliferation	O
rate	O
of	O
LV5	O
-	O
MARCH7	B-GP
cells	O
was	O
increased	O
compared	O
with	O
LV5	O
-	O
GFP	B-GP
cells	O
.	O

(	O
K	O
)	O
Cell	O
proliferation	O
was	O
determined	O
by	O
CCK	O
-	O
8	O
assay	O
.	O

(	O
L	O
,	O
M	O
)	O
Colony	O
formation	O
assay	O
.	O

A2780	O
cells	O
infected	O
with	O
LV5	O
-	O
MARCH7	B-GP
were	O
cultured	O
by	O
seeding	O
1000	O
cells	O
in	O
6	O
-	O
well	O
plates	O
and	O
counting	O
the	O
number	O
of	O
colonies	O
formed	O
in	O
2	O
weeks	O
.	O

The	O
number	O
of	O
colony	O
formation	O
of	O
LV5	O
-	O
MARCH7	B-GP
was	O
higher	O
as	O
compared	O
with	O
LV5	O
-	O
GFP	B-GP
.	O

Error	O
bars	O
represent	O
standard	O
error	O
.	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
and	O
**	O
p	O
<	O
0	O
.	O
001	O
.	O

MARCH7	B-GP
expression	O
modulates	O
cellular	O
migration	O
,	O
invasion	O
in	O
vitro	O
and	O
induces	O
F	B-GP
-	I-GP
actin	I-GP
remodeling	O

Migration	O
of	O
cells	O
and	O
invasion	O
of	O
tissues	O
are	O
important	O
prerequisites	O
for	O
tumor	B-DS
progression	O
and	O
metastasis	O
.	O

To	O
investigate	O
whether	O
MARCH7	B-GP
modulated	O
cellular	O
migration	O
and	O
invasion	O
,	O
we	O
performed	O
a	O
matrigel	O
invasion	O
assay	O
and	O
wound	O
healing	O
test	O
.	O

Wound	O
-	O
healing	O
and	O
trans	O
-	O
well	O
invasion	O
assays	O
both	O
demonstrated	O
that	O
the	O
migration	O
and	O
invasion	O
capabilities	O
of	O
SKOV3	O
cell	O
were	O
significantly	O
suppressed	O
when	O
MARCH7	B-GP
was	O
silenced	O
by	O
LV3	O
-	O
shMARCH7	O
-	O
1	O
or	O
LV3	O
-	O
shMARCH7	O
-	O
2	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
(	O
Fig	O
.	O
3A	O
,	O
3B	O
,	O
3C	O
,	O
and	O
3D	O
).	O

At	O
the	O
same	O
time	O
,	O
we	O
found	O
that	O
the	O
migration	O
and	O
invasion	O
capabilities	O
of	O
A2780	O
cells	O
were	O
significantly	O
promoted	O
when	O
MARCH7	B-GP
was	O
overexpressed	O
with	O
a	O
lentiviral	O
vector	O
expressing	O
MARCH7	B-GP
(	O
LV5	O
-	O
MARCH7	B-GP
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
(	O
Fig	O
.	O
3E	O
,	O
3F	O
,	O
3G	O
,	O
and	O
3H	O
).	O

Cellular	O
migration	O
and	O
invasion	O
is	O
dependent	O
on	O
localized	O
actin	B-GP
polymerization	O
at	O
the	O
leading	O
edge	O
of	O
the	O
cells	O
.	O

Polymerization	O
of	O
globular	O
actin	B-GP
leads	O
to	O
the	O
formation	O
of	O
long	O
fibrous	O
molecules	O
,	O
F	B-GP
-	I-GP
actin	I-GP
.	O

In	O
eukaryotic	O
cells	O
,	O
cell	O
migration	O
requires	O
the	O
formation	O
of	O
cell	O
membrane	O
extensions	O
containing	O
actin	B-GP
filaments	O
[	O
5	O
].	O

Because	O
overexpression	O
of	O
MARCH7	B-GP
in	O
A2780	O
cells	O
caused	O
a	O
marked	O
increase	O
in	O
the	O
cellular	O
migration	O
and	O
invasion	O
,	O
and	O
silencing	O
of	O
MARCH7	B-GP
expression	O
in	O
SK0V3	O
cells	O
caused	O
a	O
marked	O
decreased	O
in	O
the	O
cellular	O
migration	O
and	O
invasion	O
,	O
we	O
analyzed	O
the	O
alterations	O
in	O
the	O
pattern	O
of	O
the	O
F	B-GP
-	I-GP
actin	I-GP
in	O
SKOV3	O
and	O
A2780	O
by	O
silencing	O
or	O
ectopic	O
expression	O
MARCH7	B-GP
respectively	O
.	O

In	O
LV3	O
-	O
NC	O
infected	O
SKOV3	O
cells	O
,	O
F	B-GP
-	I-GP
actin	I-GP
staining	O
was	O
predominantly	O
localized	O
in	O
the	O
cellular	O
outgrowth	O
and	O
projections	O
.	O

In	O
contrast	O
,	O
in	O
LV3	O
-	O
shMARCH7	O
-	O
1	O
or	O
LV3	O
-	O
shMARCH7	O
-	O
2	O
infected	O
SKOV3	O
cells	O
,	O
F	B-GP
-	I-GP
actin	I-GP
staining	O
was	O
homogenous	O
throughout	O
the	O
cytoplasm	O
,	O
and	O
the	O
formation	O
of	O
membrane	O
ruffles	O
and	O
lamellipodia	B-GP
was	O
prevented	O
(	O
Fig	O
.	O
3I	O
).	O

LV5	O
-	O
GFP	B-GP
-	O
infected	O
A2780	O
cells	O
displayed	O
some	O
small	O
lamellipodia	B-GP
and	O
ruffles	O
.	O

In	O
contrast	O
,	O
LV5	O
-	O
MARCH7	B-GP
infected	O
A2780	O
cells	O
showed	O
F	B-GP
-	I-GP
actin	I-GP
reorganization	O
in	O
membrane	O
ruffles	O
and	O
lamellipodia	B-GP
(	O
Fig	O
.	O
3J	O
).	O

These	O
results	O
suggest	O
that	O
MARCH7	B-GP
can	O
modulate	O
cellular	O
dynamics	O
by	O
reorganization	O
of	O
the	O
actin	B-GP
cytoskeleton	O
.	O

(	O
A	O
,	O
B	O
)	O
Ovarian	B-DS
cancer	I-DS
SKOV3	O
cells	O
migration	O
ability	O
was	O
detected	O
by	O
the	O
wound	O
healing	O
assay	O
.	O

The	O
migration	O
of	O
LV3	O
-	O
shMARCH7	O
-	O
1	O
and	O
LV3	O
-	O
shMARCH7	O
-	O
2	O
infected	O
SKOV3	O
cells	O
was	O
lower	O
as	O
compared	O
with	O
LV3	O
-	O
NC	O
infected	O
cells	O
.	O

(	O
C	O
,	O
D	O
)	O
Ovarian	B-DS
cancer	I-DS
SKOV3	O
cells	O
invasion	O
ability	O
was	O
detected	O
by	O
Matrigel	O
invasion	O
assays	O
.	O

The	O
invasion	O
ability	O
of	O
LV3	O
-	O
shMARCH7	O
-	O
1	O
and	O
LV3	O
-	O
shMARCH7	O
-	O
2	O
infected	O
SKOV3	O
cells	O
was	O
decreased	O
compared	O
with	O
LV3	O
-	O
NC	O
infected	O
cells	O
.	O

(	O
E	O
,	O
F	O
)	O
Ovarian	B-DS
cancer	I-DS
A2780	O
cells	O
migration	O
ability	O
was	O
detected	O
by	O
wound	O
healing	O
assay	O
.	O

The	O
migration	O
ability	O
of	O
LV5	O
-	O
MARCH7	B-GP
infected	O
A2780	O
cells	O
was	O
increased	O
compared	O
with	O
LV3	O
-	O
NC	O
infected	O
cells	O
.	O

(	O
G	O
,	O
H	O
)	O
Ovarian	B-DS
cancer	I-DS
A2780	O
cells	O
invasion	O
ability	O
was	O
detected	O
by	O
Matrigel	O
invasion	O
assays	O
.	O

The	O
invasion	O
ability	O
of	O
LV5	O
-	O
MARCH7	B-GP
infected	O
A2780	O
cells	O
was	O
increased	O
compared	O
with	O
LV5	O
-	O
GFP	B-GP
infected	O
cells	O
.	O

(	O
I	O
,	O
J	O
).	O

F	B-GP
-	I-GP
actin	I-GP
staining	O
.	O

Original	O
magnification	O
,	O
400X	O
.	O

Error	O
bars	O
represent	O
standard	O
error	O
.	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
and	O
**	O
p	O
<	O
0	O
.	O
001	O
.	O

TGF	B-GP
-	I-GP
β1	I-GP
,	O
TNF	B-GP
-	I-GP
α	I-GP
and	O
IL	B-GP
-	I-GP
1β	I-GP
regulate	O
the	O
expression	O
of	O
MARCH7	B-GP

Transforming	B-GP
growth	I-GP
factor	I-GP
(	I-GP
TGF	I-GP
)-	I-GP
β1	I-GP
,	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
-	I-GP
alpha	I-GP
(	O
TNF	B-GP
-	I-GP
α	I-GP
)	O
and	O
Interleukin	B-GP
-	I-GP
1β	I-GP
are	O
expressed	O
in	O
ovarian	B-DS
cancer	I-DS
,	O
which	O
can	O
promote	O
ovarian	O
tumorigenesis	O
through	O
an	O
inflammatory	O
response	O
[	O
6	O
-	O
8	O
].	O

Hence	O
,	O
we	O
explored	O
the	O
possibility	O
of	O
whether	O
TGF	B-GP
-	I-GP
β1	I-GP
,	O
TNF	B-GP
-	I-GP
α	I-GP
,	O
and	O
interleukin	B-GP
-	I-GP
1β	I-GP
can	O
mediate	O
MARCH7	B-GP
expression	O
in	O
SKOV3	O
cells	O
.	O

Ovarian	B-DS
cancer	I-DS
SKOV3	O
cells	O
were	O
treated	O
with	O
TGF	B-GP
-	I-GP
β1	I-GP
(	O
0	O
,	O
10	O
,	O
20	O
,	O
30	O
ng	O
/	O
mL	O
),	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
0	O
,	O
10	O
,	O
20	O
,	O
30	O
ng	O
/	O
mL	O
)	O
or	O
interleukin	B-GP
-	I-GP
1β	I-GP
(	O
0	O
,	O
10	O
,	O
20	O
,	O
30	O
ng	O
/	O
mL	O
)	O
for	O
48	O
hours	O
.	O

TGF	B-GP
-	I-GP
β1	I-GP
increased	O
the	O
mRNA	O
and	O
protein	O
level	O
of	O
MARCH7	B-GP
at	O
10	O
ng	O
/	O
mL	O
than	O
that	O
untreated	O
.	O

However	O
,	O
the	O
mRNA	O
and	O
protein	O
levels	O
were	O
lower	O
in	O
cells	O
treated	O
with	O
TGF	B-GP
-	I-GP
β1	I-GP
20	O
ng	O
/	O
mL	O
or	O
30	O
ng	O
/	O
mL	O
.	O

The	O
changes	O
in	O
the	O
mRNA	O
and	O
protein	O
levels	O
of	O
MARCH7	B-GP
in	O
response	O
to	O
TNF	B-GP
-	I-GP
α	I-GP
or	O
interleukin	B-GP
-	I-GP
1β	I-GP
was	O
similar	O
to	O
that	O
with	O
TGF	B-GP
-	I-GP
β1	I-GP
treatment	O
at	O
(	O
0	O
,	O
10	O
,	O
20	O
,	O
30	O
ng	O
/	O
mL	O
)	O
(	O
Fig	O
.	O
4A	O
and	O
Fig	O
.	O

S1A	O
-	O
C	O
).	O

Our	O
results	O
indicated	O
that	O
TGF	B-GP
-	I-GP
β1	I-GP
,	O
TNF	B-GP
-	I-GP
α	I-GP
,	O
and	O
interleukin	B-GP
-	I-GP
1β	I-GP
regulated	O
MARCH7	B-GP
expression	O
to	O
promote	O
tumor	B-DS
metastasis	O
of	O
ovarian	B-DS
cancer	I-DS
.	O

Ectopic	O
expression	O
of	O
MARCH7	B-GP
increased	O
NF	B-GP
-	I-GP
κB	I-GP
and	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
signal	O
pathway	O
luciferase	B-GP
reporter	O
activity	O

Our	O
data	O
indicated	O
that	O
MARCH7	B-GP
might	O
have	O
been	O
involved	O
in	O
cellular	O
proliferation	O
,	O
migration	O
,	O
and	O
invasion	O
.	O

Hence	O
,	O
we	O
believe	O
that	O
MARCH7	B-GP
might	O
mediate	O
some	O
signal	O
pathway	O
,	O
which	O
is	O
associated	O
with	O
ovarian	B-DS
cancer	I-DS
.	O

We	O
detected	O
NF	B-GP
-	I-GP
κB	I-GP
,	O
Notch	B-GP
,	O
P53	B-GP
,	O
STAT3	B-GP
,	O
and	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
signal	O
pathway	O
luciferase	B-GP
reporter	O
activity	O
by	O
ectopic	O
expression	O
of	O
MARCH7	B-GP
in	O
ovarian	B-DS
cancer	I-DS
A2780	O
cells	O
infected	O
with	O
LV5	O
-	O
MARCH7	B-GP
.	O

We	O
found	O
that	O
ectopic	O
expression	O
of	O
MARCH7	B-GP
in	O
ovarian	B-DS
cancer	I-DS
A2780	O
cells	O
significantly	O
increased	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
and	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
pathway	O
luciferase	B-GP
reporter	O
activities	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Fig	O
.	O

S1D	O
).	O

Hence	O
,	O
we	O
hypothesize	O
that	O
MARCH7	B-GP
may	O
regulate	O
NF	B-GP
-	I-GP
κB	I-GP
and	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
signal	O
pathway	O
.	O

MARCH7	B-GP
mediates	O
NF	B-GP
-	I-GP
kB	I-GP
pathway	O
in	O
ovarian	B-DS
cancer	I-DS
SKOV3	O
and	O
A2780	O
cells	O

The	O
silencing	O
of	O
MARCH7	B-GP
in	O
SKOV3	O
cells	O
caused	O
a	O
marked	O
decrease	O
in	O
NF	B-GP
-	I-GP
κB	I-GP
luciferase	B-GP
activity	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
that	O
was	O
consistent	O
with	O
the	O
above	O
results	O
(	O
Fig	O
.	O

S1E	O
).	O

P65	B-GP
and	O
P50	B-GP
protein	O
levels	O
were	O
decreased	O
in	O
SKOV3	O
cells	O
when	O
MARCH7	B-GP
was	O
silenced	O
(	O
Fig	O
.	O
4B	O
(	O
I	O
)).	O

Ectopic	O
MARCH7	B-GP
gene	O
expression	O
in	O
A2780	O
cells	O
increased	O
the	O
protein	O
level	O
P65	B-GP
and	O
P50	B-GP
(	O
Fig	O
.	O
4B	O
(	O
II	O
)).	O

We	O
tested	O
whether	O
MARCH7	B-GP
regulated	O
nuclear	O
localization	O
of	O
individual	O
NF	B-GP
-	I-GP
κB	I-GP
in	O
ovarian	B-DS
cancer	I-DS
cells	O
such	O
as	O
SKOV3	O
and	O
A2780	O
.	O

The	O
decrease	O
in	O
nuclear	O
translocation	O
of	O
NF	B-GP
kB	I-GP
p65	I-GP
and	O
P50	B-GP
after	O
transfection	O
to	O
SKOV3	O
cells	O
were	O
observed	O
with	O
LV3	O
-	O
shMARCH7	O
-	O
1	O
or	O
LV3	O
-	O
shMARCH7	O
-	O
2	O
as	O
compared	O
to	O
that	O
of	O
LV3	O
-	O
NC	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
(	O
Fig	O
.	O
5A	O
and	O
5B	O
).	O

Increase	O
in	O
nuclear	O
translocation	O
of	O
NF	B-GP
kB	I-GP
p65	I-GP
and	O
P50	B-GP
were	O
observed	O
after	O
infection	B-DS
of	O
A2780	O
cells	O
with	O
LV5	O
-	O
MARCH7	B-GP
as	O
compared	O
with	O
that	O
of	O
LV5	O
-	O
GFP	B-GP
(	O
P	O
<	O
0	O
.	O
05	O
)	O
(	O
Fig	O
.	O
5A	O
and	O
5B	O
).	O

Next	O
,	O
we	O
determined	O
whether	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
could	O
regulate	O
MARCH7	B-GP
.	O

Inhibition	O
of	O
NF	B-GP
-	I-GP
κB	I-GP
signaling	O
in	O
SKOV3	O
cells	O
by	O
PTDC	B-GP
caused	O
a	O
reduction	O
in	O
the	O
levels	O
of	O
mRNA	O
and	O
protein	O
of	O
MARCH7	B-GP
,	O
with	O
the	O
reduction	O
corresponding	O
to	O
an	O
increase	O
in	O
the	O
PTDC	B-GP
concentration	O
(	O
0	O
,	O
10	O
,	O
30	O
50	O
uM	O
)	O
(	O
Fig	O
.	O
4A	O
and	O
S1F	O
).	O

The	O
mRNA	O
and	O
protein	O
level	O
of	O
MARCH7	B-GP
in	O
SKOV3	O
cells	O
were	O
lowered	O
after	O
transfection	O
with	O
P50	B-GP
or	O
P65	B-GP
(	O
Fig	O
.	O
4A	O
and	O
S1G	O
).	O

Our	O
data	O
suggested	O
MARCH7	B-GP
interact	O
with	O
NF	B-GP
kB	I-GP
pathway	O
.	O

(	O
A	O
)	O
The	O
expression	O
of	O
MARCH7	B-GP
protein	O
level	O
in	O
SKOV3	O
cells	O
was	O
regulated	O
by	O
TGF	B-GP
-	I-GP
β1	I-GP
,	O
TNF	B-GP
-	I-GP
α	I-GP
,	O
IL	B-GP
-	I-GP
1β	I-GP
,	O
PTDC	B-GP
,	O
NFkB	B-GP
P50	I-GP
and	O
NFkB	B-GP
P65	I-GP
.(	O
B	O
)	O
The	O
protein	O
expression	O
level	O
in	O
SKOV3	O
and	O
A2780	O
cells	O
of	O
NFkB	B-GP
P65	I-GP
,	O
NFkB	B-GP
P50	I-GP
,	O
E	B-GP
-	I-GP
cadherin	I-GP
and	O
β	B-GP
-	I-GP
catenin	I-GP
was	O
detected	O
by	O
western	O
blot	O
.	O

(	O
C	O
-	O
I	O
)	O
A	O
putative	O
binding	O
site	O
targeted	O
by	O
miR	O
-	O
101	O
was	O
predicted	O
to	O
be	O
located	O
in	O
3	O
′	O
UTR	O
of	O
MARCH7	B-GP
mRNA	O
.	O

(	O
C	O
-	O
II	O
)	O
SKOV3	O
cells	O
were	O
co	O
-	O
transfected	O
with	O
miR	O
-	O
101	O
mimics	O
or	O
control	O
RNA	O
[	O
negative	O
control	O
(	O
NC	O
)]	O
with	O
luciferase	B-GP
reporter	O
plasmids	O
containing	O
either	O
wild	O
type	O
(	O
pMIR	O
-	O
MARCH7	B-GP
-	O
3UTR	O
)	O
or	O
mutant	O
3	O
′	O
UTR	O
(	O
pMIR	O
-	O
MARCH7	B-GP
-	O
3UTRm	O
)	O
of	O
MARCH7	B-GP
gene	O
.	O

Luciferase	B-GP
expression	O
was	O
measured	O
.	O

The	O
fold	O
changes	O
of	O
relative	O
luciferase	B-GP
activity	O
in	O
miR	O
-	O
101	O
mimics	O
with	O
indicated	O
plasmids	O
transfected	O
cells	O
were	O
normalized	O
to	O
NC	O
with	O
corresponding	O
indicated	O
plasmids	O
transtected	O
cells	O
,	O
respectively	O
.	O

(	O
C	O
-	O
III	O
)	O
The	O
expression	O
of	O
MARCH7	B-GP
protein	O
levels	O
was	O
detected	O
by	O
western	O
blot	O
.	O

(	O
D	O
)	O
Ovarian	B-DS
cancer	I-DS
SKOV3	O
cells	O
migration	O
ability	O
was	O
detected	O
by	O
the	O
wound	O
healing	O
assay	O
.	O

(	O
E	O
)	O
Ovarian	B-DS
cancer	I-DS
SKOV3	O
cells	O
invasion	O
ability	O
was	O
detected	O
by	O
Matrigel	O
invasion	O
assays	O
.	O

(	O
F	O
)	O
Cell	O
proliferation	O
was	O
determined	O
by	O
CCK	O
-	O
8	O
assay	O
.	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
and	O
**	O
p	O
<	O
0	O
.	O
001	O
.	O

MARCH7	B-GP
regulates	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
pathway	O
in	O
ovarian	B-DS
cancer	I-DS
SKOV3	O
and	O
A2780	O
cell	O

Consistent	O
with	O
the	O
above	O
results	O
,	O
the	O
level	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
protein	O
expressed	O
in	O
LV5	O
-	O
MARCH7	B-GP
-	O
infected	O
A2780	O
cells	O
were	O
significantly	O
higher	O
than	O
that	O
of	O
LV5	O
-	O
GFP	B-GP
-	O
infected	O
A2780	O
cells	O
(	O
Fig	O
.	O
4B	O
(	O
I	O
)).	O

In	O
contrast	O
,	O
LV3	O
-	O
shMARCH7	O
-	O
1	O
or	O
LV3	O
-	O
shMARCH7	O
-	O
2	O
infected	O
cells	O
decreased	O
TOP	O
-	O
flash	O
luciferase	B-GP
activity	O
,	O
and	O
the	O
expression	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
protein	O
than	O
that	O
of	O
LV3	O
-	O
NC	O
-	O
infected	O
SKOV3	O
cells	O
(	O
Fig	O
.	O
4B	O
(	O
II	O
)	O
and	O
S1H	O
).	O

Non	O
-	O
phosphorylated	O
β	B-GP
-	I-GP
catenin	I-GP
has	O
been	O
identified	O
as	O
the	O
transcriptionally	O
active	O
form	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
in	O
the	O
nucleus	O
.	O

Therefore	O
,	O
we	O
determined	O
if	O
MARCH7	B-GP
promoted	O
β	B-GP
-	I-GP
catenin	I-GP
translocation	O
to	O
the	O
nuclei	O
of	O
SKOV3	O
and	O
A2780	O
cells	O
.	O

A2780	O
cells	O
exposed	O
to	O
LV5	O
-	O
MARCH7	B-GP
resulted	O
in	O
significantly	O
higher	O
levels	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
proteins	O
in	O
both	O
the	O
cytoplasm	O
and	O
the	O
nuclei	O
,	O
relative	O
to	O
LV5	O
-	O
GFP	B-GP
-	O
infected	O
A2780	O
cells	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
(	O
Fig	O
.	O
5A	O
and	O
5B	O
).	O

Conversely	O
,	O
LV3	O
-	O
shMARCH7	O
-	O
1	O
or	O
LV3	O
-	O
shMARCH7	O
-	O
2	O
infected	O
SKOV3	O
cells	O
showed	O
a	O
decrease	O
in	O
both	O
,	O
the	O
cytoplasmic	O
and	O
nuclear	O
expression	O
levels	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
relative	O
to	O
LV3	O
-	O
NC	O
-	O
infected	O
SKOV3	O
cells	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
(	O
Fig	O
.	O
5A	O
and	O
5B	O
).	O

These	O
findings	O
suggested	O
that	O
MARCH7	B-GP
activation	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
results	O
in	O
nuclear	O
translocation	O
and	O
accumulation	O
,	O
thereby	O
enabling	O
it	O
to	O
regulate	O
expression	O
of	O
genes	O
associated	O
with	O
tumorigenesis	O
.	O

C	B-GP
-	I-GP
myc	I-GP
,	O
sp5	B-GP
,	O
lef1	B-GP
play	O
key	O
roles	O
in	O
the	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
signaling	O
pathway	O
[	O
9	O
-	O
11	O
].	O

Therefore	O
,	O
we	O
determined	O
the	O
expression	O
of	O
their	O
respective	O
mRNAs	O
by	O
qPCR	O
by	O
silencing	O
MARCH7	B-GP
in	O
SKOV3	O
cells	O
,	O
and	O
ectopic	O
expression	O
of	O
MARCH7	B-GP
in	O
A2780	O
cells	O
.	O

The	O
results	O
showed	O
that	O
mRNA	O
levels	O
of	O
c	B-GP
-	I-GP
myc	I-GP
,	O
sp5	B-GP
,	O
lef1	B-GP
were	O
significantly	O
higher	O
in	O
LV5	O
-	O
MARCH7	B-GP
-	O
infected	O
A2780	O
cells	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
(	O
Fig	O
.	O

S1I	O
);	O
whereas	O
,	O
they	O
were	O
significantly	O
lower	O
in	O
LV3	O
-	O
shMARCH7	O
-	O
1	O
or	O
LV3	O
-	O
shMARCH7	O
-	O
2	O
infected	O
SKOV3	O
cells	O
,	O
relative	O
to	O
LV3	O
-	O
NC	O
infected	O
SKOV3	O
cells	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
(	O
Fig	O
.	O

S1J	O
).	O

(	O
A	O
)	O
The	O
expression	O
of	O
NFkB	B-GP
P65	I-GP
,	O
NFkB	B-GP
P50	I-GP
,	O
and	O
β	B-GP
-	I-GP
catenin	I-GP
was	O
detected	O
by	O
immunofluorescence	O
staining	O
in	O
ovarian	B-DS
cancer	I-DS
SKOV3	O
cells	O
(	O
LV3	O
-	O
shMARCH7	O
-	O
1	O
or	O
LV3	O
-	O
shMARCH7	O
-	O
2	O
infected	O
)	O
and	O
A2780	O
cells	O
(	O
LV5	O
-	O
MARCH7	B-GP
infected	O
).	O

(	O
B	O
).	O

The	O
nuclear	O
translocation	O
of	O
NFkB	B-GP
P65	I-GP
,	O
NFkB	B-GP
P50	I-GP
,	O
and	O
β	B-GP
-	I-GP
catenin	I-GP
was	O
decreased	O
in	O
LV3	O
-	O
shMARCH7	O
-	O
1	O
or	O
LV3	O
-	O
shMARCH7	O
-	O
2	O
infected	O
ovarian	B-DS
cancer	I-DS
SKOV3	O
cells	O
as	O
compared	O
with	O
LV3	O
-	O
NC	O
infected	O
cells	O
.	O

The	O
nuclear	O
translocation	O
of	O
NFkB	B-GP
P65	I-GP
,	O
NFkB	B-GP
P50	I-GP
,	O
and	O
β	B-GP
-	I-GP
catenin	I-GP
was	O
increased	O
in	O
LV5	O
-	O
MARCH7	B-GP
infected	O
ovarian	B-DS
cancer	I-DS
A2780	O
cells	O
compared	O
with	O
LV5	O
-	O
GFP	B-GP
infected	O
cells	O
.	O

Original	O
magnification	O
×	O
200	O
.	O

Data	O
are	O
expressed	O
as	O
Mean	O
±	O
SD	O
from	O
three	O
independent	O
experiments	O
.	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
and	O
**	O
p	O
<	O
0	O
.	O
001	O
.	O

MARCH7	B-GP
regulates	O
the	O
protein	O
levels	O
of	O
E	B-GP
-	I-GP
cadherin	I-GP
in	O
ovarian	B-DS
cancer	I-DS
SKOV3	O
cells	O

Intercellular	O
adhesion	O
correlates	O
with	O
the	O
presence	O
of	O
E	B-GP
-	I-GP
cadherin	I-GP
and	O
catenin	B-GP
complexes	O
.	O

It	O
regulates	O
β	B-GP
-	I-GP
catenin	I-GP
transport	O
to	O
the	O
cell	O
nucleus	O
to	O
activate	O
the	O
transcription	O
of	O
many	O
genes	O
[	O
12	O
,	O
13	O
].	O

Therefore	O
,	O
we	O
explored	O
whether	O
MARCH7	B-GP
regulated	O
the	O
expression	O
level	O
of	O
E	B-GP
-	I-GP
cadherin	I-GP
protein	O
.	O

The	O
results	O
showed	O
that	O
protein	O
levels	O
of	O
E	B-GP
-	I-GP
cadherin	I-GP
were	O
significantly	O
decreased	O
in	O
LV5	O
-	O
MARCH7	B-GP
-	O
infected	O
A2780	O
cells	O
(	O
Fig	O
.	O
4B	O
(	O
I	O
));	O
whereas	O
,	O
they	O
were	O
significantly	O
increased	O
in	O
LV3	O
-	O
shMARCH7	O
-	O
1	O
or	O
LV3	O
-	O
shMARCH7	O
-	O
2	O
infected	O
SKOV3	O
cells	O
,	O
relative	O
to	O
LV3	O
-	O
NC	O
infected	O
SKOV3	O
cells	O
(	O
Fig	O
.	O
4B	O
(	O
II	O
))	O

MiR	O
-	O
101	O
regulates	O
MARCH7	B-GP
expression	O
in	O
ovarian	B-DS
cancers	I-DS

Bioinformatics	O
analyses	O
using	O
multiple	O
algorithms	O
showed	O
that	O
MARCH7	B-GP
is	O
a	O
predictive	O
target	O
of	O
miR	O
-	O
101	O
(	O
http	O
://	O
www	O
.	O
targetscan	O
.	O
org	O
/).	O

Thus	O
,	O
we	O
experimentally	O
verified	O
whether	O
miR	O
-	O
101	O
modulated	O
MARCH7	B-GP
expression	O
in	O
SKOV3	O
cells	O
.	O

We	O
predicted	O
that	O
miR	O
-	O
101	O
-	O
specific	O
binding	O
site	O
was	O
located	O
within	O
the	O
3	O
′	O
UTR	O
of	O
MARCH7	B-GP
mRNA	O
(	O
Fig	O
.	O
4C	O
(	O
I	O
)).	O

We	O
constructed	O
a	O
vector	O
to	O
investigate	O
if	O
miR	O
-	O
101	O
could	O
directly	O
target	O
MARCH7	B-GP
3	O
′	O
UTR	O
.	O

We	O
found	O
that	O
miR	O
-	O
101	O
markedly	O
inhibited	O
luciferase	B-GP
activity	O
when	O
MARCH7	B-GP
3	O
′	O
UTR	O
was	O
inserted	O
downstream	O
of	O
luciferase	B-GP
cDNA	O
in	O
our	O
reporter	O
vector	O
(	O
pMIR	O
-	O
MARCH73UTR	O
).	O

In	O
contrast	O
,	O
no	O
significant	O
suppressive	O
effect	O
on	O
luciferase	B-GP
activity	O
was	O
observed	O
in	O
cells	O
transfected	O
with	O
a	O
control	O
vector	O
with	O
mutant	O
MARCH7	B-GP
3	O
′	O
UTR	O
(	O
MIR	O
-	O
MARCH73UTRm	O
),	O
when	O
miR	O
-	O
101	O
expression	O
was	O
elevated	O
(	O
Fig	O
.	O
4C	O
(	O
II	O
)).	O

We	O
also	O
found	O
that	O
miR	O
-	O
101	O
mimics	O
could	O
downregulate	O
the	O
mRNA	O
and	O
protein	O
level	O
of	O
MARCH7	B-GP
(	O
Fig	O
.	O
4C	O
(	O
III	O
)	O
and	O
S1K	O
).	O

We	O
also	O
found	O
that	O
expression	O
of	O
miR	O
-	O
101	O
inhibited	O
proliferation	O
,	O
migration	O
and	O
invasion	O
of	O
SKOV3	O
cells	O
.	O

The	O
phenotypes	O
can	O
be	O
partially	O
restored	O
expression	O
of	O
a	O
miR	O
-	O
101	O
resistant	O
MARCH7	B-GP
(	O
Fig	O
.	O
4D	O
,	O
4E	O
and	O
4F	O
).	O

These	O
data	O
indicate	O
that	O
MARCH7	B-GP
is	O
a	O
direct	O
target	O
of	O
miR	O
-	O
101	O
.	O

Downregulation	O
of	O
MARCH7	B-GP
abolished	O
tumorigenicity	O
of	O
ovarian	B-DS
cancer	I-DS
SKOV3	O
cell	O

The	O
role	O
of	O
MARCH7	B-GP
in	O
tumor	B-DS
formation	O
of	O
ovarian	B-DS
cancer	I-DS
SKOV3	O
cells	O
was	O
investigated	O
in	O
an	O
animal	B-OG
model	O
.	O

LV3	O
-	O
shMARCH7	O
-	O
1	O
and	O
LV3	O
-	O
NC	O
infected	O
SKOV3	O
cells	O
formed	O
tumors	B-DS
in	O
all	O
nude	B-OG
mice	I-OG
.	O

The	O
average	O
weight	O
of	O
tumors	B-DS
was	O
significantly	O
lower	O
in	O
LV3	O
-	O
shMARCH7	O
-	O
1	O
infected	O
group	O
than	O
that	O
in	O
LV3	O
-	O
NC	O
infected	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Fig	O
.	O
6A	O
and	O
6B	O
).	O

The	O
average	O
volume	O
of	O
tumors	B-DS
in	O
LV3	O
-	O
shMARCH7	O
-	O
1	O
infected	O
group	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
LV3	O
-	O
NC	O
infected	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
;	O
Fig	O
.	O
6A	O
and	O
6B	O
).	O

IHC	O
revealed	O
that	O
the	O
expression	O
of	O
MARCH7	B-GP
,	O
P50	B-GP
,	O
P65	B-GP
and	O
β	B-GP
-	I-GP
catenin	I-GP
in	O
tumors	B-DS
from	O
LV3	O
-	O
shMARCH7	O
-	O
1	O
infected	O
group	O
was	O
lower	O
than	O
that	O
in	O
the	O
LV3	O
-	O
NC	O
infected	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
(	O
Fig	O
.	O
6C	O
and	O
S2A	O
).	O

These	O
data	O
show	O
that	O
silencing	O
MARCH7	B-GP
blocks	O
tumor	B-DS
formation	O
in	O
vivo	O
.	O
MARCH7	B-GP
can	O
regulate	O
the	O
expression	O
of	O
P50	B-GP
,	O
P65	B-GP
and	O
β	B-GP
-	I-GP
catenin	I-GP
in	O
vivo	O
.	O

We	O
also	O
found	O
that	O
A2780	O
cells	O
infected	O
LV5	O
-	O
MARCH7	B-GP
increased	O
the	O
average	O
weight	O
of	O
tumors	B-DS
and	O
the	O
average	O
volume	O
of	O
tumors	B-DS
than	O
that	O
of	O
the	O
LV5	O
-	O
GFP	B-GP
infected	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
;	O
Fig	O
.	O
6D	O
and	O
6E	O
).	O

IHC	O
revealed	O
that	O
the	O
expression	O
of	O
MARCH7	B-GP
,	O
P50	B-GP
,	O
P65	B-GP
and	O
β	B-GP
-	I-GP
catenin	I-GP
in	O
tumors	B-DS
from	O
LV5	O
-	O
MARCH7	B-GP
infected	O
group	O
was	O
increased	O
than	O
that	O
in	O
the	O
LV5	O
-	O
GFP	B-GP
infected	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
(	O
Fig	O
.	O
6F	O
and	O
S2B	O
).	O

These	O
data	O
show	O
that	O
MARCH7	B-GP
promoted	O
tumor	B-DS
formation	O
in	O
vivo	O
.	O

MARCH7	B-GP
regulated	O
tumorigenesis	O
in	O
nude	B-OG
mice	I-OG
model	O

(	O
A	O
,	O
B	O
)	O
Mean	O
tumor	B-DS
volume	O
and	O
weight	O
on	O
day	O
21	O
after	O
tumor	B-DS
cell	O
injection	O
.	O

LV3	O
-	O
shMARCH7	O
-	O
1	O
or	O
LV3	O
-	O
NC	O
infected	O
SKOV3	O
cells	O
were	O
implanted	O
s	O
.	O
c	O
.	O
into	O
the	O
left	O
armpit	O
.	O

(	O
C	O
).	O

Immunohistochemical	O
analysis	O
of	O
MARCH7	B-GP
,	O
NFkB	B-GP
P65	I-GP
,	O
NFkB	B-GP
P50	I-GP
,	O
and	O
β	B-GP
-	I-GP
catenin	I-GP
expression	O
were	O
performed	O
on	O
tumor	B-DS
xenografts	O
.	O

Representative	O
images	O
are	O
shown	O
(	O
original	O
magnification	O
×	O
200	O
).	O

(	O
D	O
,	O
E	O
)	O
Mean	O
tumor	B-DS
volume	O
and	O
weight	O
on	O
day	O
21	O
after	O
tumor	B-DS
cell	O
injection	O
.	O

LV5	O
-	O
GFP	B-GP
or	O
LV5	O
-	O
MARCH7	B-GP
infected	O
A2780	O
cells	O
were	O
implanted	O
s	O
.	O
c	O
.	O
into	O
the	O
left	O
armpit	O
.	O

(	O
F	O
)	O
Immunohistochemical	O
analysis	O
of	O
MARCH7	B-GP
,	O
NFkB	B-GP
P65	I-GP
,	O
NFkB	B-GP
P50	I-GP
,	O
and	O
β	B-GP
-	I-GP
catenin	I-GP
expression	O
were	O
performed	O
on	O
tumor	B-DS
xenografts	O
.	O

Representative	O
images	O
are	O
shown	O
(	O
original	O
magnification	O
×	O
200	O
).	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
and	O
**	O
p	O
<	O
0	O
.	O
001	O
.	O

DISCUSSION	O

In	O
this	O
study	O
,	O
we	O
noted	O
that	O
MARCH7	B-GP
expression	O
was	O
higher	O
in	O
ovarian	B-DS
cancer	I-DS
tissues	O
,	O
compared	O
to	O
normal	O
ovarian	O
tissues	O
.	O

We	O
also	O
observed	O
that	O
overexpression	O
of	O
MARCH7	B-GP
in	O
ovarian	B-DS
cancer	I-DS
correlated	O
with	O
tumor	B-DS
stage	O
and	O
histological	O
grades	O
.	O

Our	O
results	O
showed	O
that	O
up	O
-	O
regulation	O
of	O
MARCH7	B-GP
expression	O
in	O
ovarian	B-DS
cancer	I-DS
increased	O
cellular	O
migration	O
,	O
invasion	O
,	O
and	O
cell	O
proliferation	O
in	O
vitro	O
with	O
remarkable	O
changes	O
in	O
the	O
cytoskeleton	O
.	O

These	O
results	O
suggest	O
that	O
elevated	O
levels	O
of	O
MARCH7	B-GP
aids	O
in	O
the	O
progress	O
of	O
ovarian	B-DS
cancer	I-DS
,	O
and	O
promotes	O
an	O
aggressive	O
behavior	O
,	O
indicating	O
that	O
MARCH7	B-GP
may	O
function	O
as	O
a	O
novel	O
tumor	B-DS
marker	O
and	O
a	O
potential	O
therapeutic	O
target	O
for	O
ovarian	B-DS
cancer	I-DS
.	O

Our	O
data	O
also	O
demonstrates	O
that	O
MARCH7	B-GP
can	O
regulate	O
nuclear	B-GP
factor	I-GP
kB	I-GP
(	O
NF	B-GP
-	I-GP
kB	I-GP
)	O
and	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
pathway	O
,	O
and	O
that	O
MIR	O
-	O
101	O
controls	O
MARCH7	B-GP
by	O
targeting	O
MATCH7	B-GP
3	O
′	O
UTR	O
region	O
.	O

In	O
addition	O
to	O
the	O
investigation	O
of	O
MARCH7	B-GP
in	O
ovarian	B-DS
cancer	I-DS
,	O
we	O
explored	O
the	O
role	O
of	O
MARCH7	B-GP
in	O
ovarian	B-DS
cancer	I-DS
.	O

We	O
found	O
that	O
inhibiting	O
MARCH7	B-GP
expression	O
in	O
ovarian	B-DS
cancer	I-DS
SKOV3	O
cells	O
suppressed	O
cancer	B-DS
cell	O
activities	O
,	O
whereas	O
overexpression	O
MARCH7	B-GP
in	O
ovarian	B-DS
cancer	I-DS
A2780	O
cells	O
increased	O
cancer	B-DS
cell	O
activities	O
such	O
as	O
growth	O
,	O
migration	O
,	O
and	O
invasion	O
.	O

In	O
a	O
living	O
cell	O
,	O
the	O
actin	B-GP
cytoskeleton	O
continuously	O
undergoes	O
remodeling	O
at	O
a	O
constant	O
rate	O
.	O

This	O
dynamics	O
are	O
based	O
on	O
predictive	O
controlled	O
equilibrium	O
,	O
and	O
a	O
dynamic	O
balance	O
of	O
actin	B-GP
filaments	O
.	O

This	O
regulation	O
is	O
crucial	O
for	O
cell	O
motility	O
,	O
and	O
cancer	B-DS
cell	O
invasion	O
[	O
14	O
-	O
16	O
].	O

In	O
our	O
study	O
,	O
we	O
found	O
that	O
MARCH7	B-GP
regulated	O
localization	O
in	O
the	O
cellular	O
,	O
membrane	O
lamellipodia	B-GP
,	O
and	O
ruffles	O
.	O

These	O
results	O
indicate	O
that	O
MARCH7	B-GP
is	O
a	O
novel	O
regulator	O
of	O
ovarian	B-DS
cancer	I-DS
progression	O
through	O
its	O
effect	O
on	O
actin	B-GP
cytoskeletal	O
alterations	O
.	O

Most	O
importantly	O
,	O
downregulation	O
of	O
MARCH7	B-GP
in	O
ovarian	B-DS
cancer	I-DS
cells	O
could	O
abolish	O
their	O
tumorigenecity	O
.	O

Until	O
now	O
,	O
there	O
is	O
no	O
study	O
implicating	O
MARCH7	B-GP
in	O
the	O
pathogenesis	O
of	O
cancer	B-DS
,	O
the	O
mechanisms	O
of	O
MARCH7	B-GP
in	O
cancer	B-DS
development	O
and	O
progression	O
are	O
poorly	O
known	O
.	O

NF	B-GP
κB	I-GP
and	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
pathway	O
are	O
involved	O
in	O
cancer	B-DS
development	O
and	O
progression	O
,	O
in	O
various	O
carcinomas	B-DS
including	O
ovarian	B-DS
cancer	I-DS
,	O
breast	B-DS
cancer	I-DS
,	O
endometrial	B-DS
cancer	I-DS
,	O
cervical	B-DS
cancer	I-DS
[	O
17	O
-	O
23	O
].	O

In	O
human	B-OG
ovarian	B-DS
carcinoma	I-DS
,	O
there	O
is	O
constitutive	O
activation	O
of	O
NF	B-GP
-	I-GP
κB	I-GP
,	O
which	O
leads	O
to	O
uncontrolled	O
growth	O
,	O
anti	O
-	O
apoptosis	O
,	O
and	O
immune	O
evasion	O
[	O
24	O
].	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
ectopic	O
expression	O
of	O
MARCH7	B-GP
in	O
ovarian	B-DS
cancer	I-DS
cells	O
increased	O
NF	B-GP
-	I-GP
κB	I-GP
activity	O
.	O

In	O
contrast	O
,	O
downregulation	O
of	O
MARCH7	B-GP
in	O
ovarian	B-DS
cancer	I-DS
decreased	O
NF	B-GP
-	I-GP
κB	I-GP
activity	O
,	O
especially	O
the	O
p65	B-GP
and	O
p50	B-GP
subunits	O
of	O
NF	B-GP
-	I-GP
kB	I-GP
protein	O
.	O

NF	B-GP
-	I-GP
kB	I-GP
p65	B-GP
is	O
the	O
major	O
subunit	O
involved	O
in	O
ovarian	B-DS
cancer	I-DS
development	O
and	O
progression	O
[	O
25	O
].	O

In	O
our	O
experiments	O
,	O
the	O
silencing	O
of	O
MARCH7	B-GP
expression	O
in	O
ovarian	B-DS
cancer	I-DS
reduced	O
P50	B-GP
and	O
P65	B-GP
protein	O
levels	O
;	O
ectopic	O
expression	O
of	O
MARCH7	B-GP
in	O
ovarian	B-DS
cancer	I-DS
increased	O
the	O
protein	O
level	O
of	O
P50	B-GP
and	O
P65	B-GP
.	O

We	O
also	O
observed	O
that	O
upregulation	O
MARCH7	B-GP
in	O
ovarian	B-DS
cancer	I-DS
A2780	O
cells	O
promoted	O
the	O
P50	B-GP
and	O
P65	B-GP
translocation	O
to	O
the	O
nucleus	O
;	O
downregulation	O
of	O
MARCH7	B-GP
in	O
ovarian	B-DS
cancer	I-DS
SKOV3	O
cells	O
inhibited	O
P50	B-GP
and	O
P65	B-GP
translocation	O
to	O
the	O
nucleus	O
.	O

To	O
further	O
study	O
the	O
relation	O
between	O
MARCH7	B-GP
and	O
NF	B-GP
kB	I-GP
,	O
we	O
tried	O
inhibiting	O
NF	B-GP
kB	I-GP
with	O
PDTC	O
(	O
Ammonium	O
pyrrolidinedithiocarbamate	O
),	O
P50	B-GP
siRNA	O
or	O
/	O
and	O
P65	B-GP
siRNA	O
.	O

We	O
found	O
that	O
PDTC	O
,	O
P50	B-GP
siRNA	O
or	O
/	O
and	O
P65	B-GP
siRNA	O
significantly	O
reduced	O
the	O
mRNA	O
and	O
protein	O
level	O
of	O
MARCH7	B-GP
.	O

This	O
suggested	O
that	O
NF	B-GP
kB	I-GP
can	O
regulate	O
the	O
expression	O
of	O
MARCH7	B-GP
in	O
ovarian	B-DS
cancer	I-DS
.	O

Our	O
data	O
indicated	O
that	O
NF	B-GP
kB	I-GP
interaction	O
with	O
MARCH7	B-GP
was	O
crucial	O
for	O
the	O
progress	O
of	O
ovarian	B-DS
cancer	I-DS
.	O

Elevation	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
in	O
the	O
cytosol	O
and	O
the	O
nucleus	O
can	O
occur	O
independently	O
through	O
various	O
pathways	O
[	O
25	O
,	O
26	O
].	O

Furthermore	O
,	O
β	B-GP
-	I-GP
catenin	I-GP
is	O
a	O
central	O
factor	O
in	O
canonical	O
Wnt	B-GP
signaling	O
[	O
27	O
].	O

We	O
found	O
that	O
ectopic	O
expression	O
of	O
MARCH7	B-GP
in	O
ovarian	B-DS
cancer	I-DS
A2780	O
cells	O
increased	O
the	O
expression	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
in	O
the	O
cytoplasm	O
and	O
promote	O
its	O
translocation	O
to	O
the	O
nucleus	O
.	O

Downregulation	O
of	O
MARCH7	B-GP
in	O
ovarian	B-DS
cancer	I-DS
SKOV3	O
cells	O
decreased	O
the	O
expression	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
in	O
the	O
cytoplasm	O
and	O
repressed	O
its	O
translocation	O
to	O
the	O
nucleus	O
.	O

These	O
results	O
confirmed	O
that	O
MARCH7	B-GP
promoted	O
β	B-GP
-	I-GP
catenin	I-GP
translocation	O
to	O
the	O
nucleus	O
in	O
ovarian	B-DS
cancer	I-DS
cells	O
.	O

Once	O
within	O
the	O
nucleus	O
,	O
β	B-GP
-	I-GP
catenin	I-GP
regulates	O
expression	O
of	O
genes	O
involved	O
in	O
the	O
activation	O
of	O
the	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
signaling	O
pathway	O
,	O
including	O
sp5	B-GP
,	O
lef1	B-GP
and	O
c	B-GP
-	I-GP
myc	I-GP
.	O

We	O
had	O
shown	O
that	O
MARCH7	B-GP
upregulated	O
β	B-GP
-	I-GP
catenin	I-GP
,	O
therefore	O
,	O
to	O
test	O
whether	O
MARCH7	B-GP
may	O
also	O
be	O
implicated	O
in	O
regulating	O
the	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
pathway	O
,	O
we	O
investigated	O
its	O
regulatory	O
effect	O
on	O
TopFlash	O
reporter	O
activity	O
,	O
sp5	B-GP
,	O
lef1	B-GP
and	O
c	B-GP
-	I-GP
myc	I-GP
.	O

Our	O
results	O
showed	O
that	O
MARCH7	B-GP
mediated	O
TopFlash	O
reporter	O
activity	O
and	O
expression	O
of	O
sp5	B-GP
,	O
lef1	B-GP
,	O
and	O
c	B-GP
-	I-GP
myc	I-GP
mRNA	O
.	O

Based	O
on	O
these	O
findings	O
,	O
we	O
concluded	O
that	O
MARCH7	B-GP
participated	O
in	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
signaling	O
in	O
human	B-OG
ovarian	B-DS
cancer	I-DS
cells	O
.	O

β	B-GP
-	I-GP
catenin	I-GP
involved	O
in	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
pathway	O
and	O
intercellular	O
adhesion	O
,	O
which	O
is	O
causally	O
correlated	O
with	O
the	O
existence	O
of	O
E	B-GP
-	I-GP
cadherin	I-GP
and	O
catenin	B-GP
complexes	O
.	O

The	O
adhesive	O
properties	O
of	O
E	B-GP
-	I-GP
cadherin	I-GP
correlated	O
with	O
the	O
junctions	O
with	O
β	B-GP
-	I-GP
catenin	I-GP
.	O

In	O
cancer	B-DS
cells	O
,	O
it	O
plays	O
an	O
important	O
role	O
in	O
cell	O
signaling	O
due	O
to	O
the	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
signaling	O
pathway	O
,	O
which	O
impedes	O
β	B-GP
-	I-GP
catenin	I-GP
degradation	O
in	O
the	O
cytoplasm	O
,	O
resulting	O
in	O
protein	O
accumulation	O
and	O
transport	O
to	O
the	O
cell	O
nucleus	O
to	O
activate	O
the	O
transcription	O
of	O
many	O
genes	O
[	O
12	O
,	O
13	O
].	O

The	O
results	O
of	O
this	O
study	O
showed	O
that	O
ectopic	O
expression	O
of	O
MARCH7	B-GP
in	O
ovarian	B-DS
cancer	I-DS
A2780	O
cells	O
reduced	O
the	O
protein	O
levels	O
of	O
E	B-GP
-	I-GP
cadherin	I-GP
.	O

In	O
contrast	O
,	O
silencing	O
of	O
MARCH7	B-GP
expression	O
in	O
ovarian	B-DS
cancer	I-DS
SKOV3	O
cells	O
significantly	O
increased	O
the	O
protein	O
level	O
of	O
E	B-GP
-	I-GP
cadherin	I-GP
.	O

It	O
indicates	O
that	O
MARCH7	B-GP
reduced	O
E	B-GP
-	I-GP
cadherin	I-GP
to	O
promote	O
β	B-GP
-	I-GP
catenin	I-GP
transport	O
to	O
the	O
cell	O
nucleus	O
.	O

MicroRNA	O
-	O
101	O
is	O
decreased	O
in	O
epithelial	B-DS
ovarian	I-DS
cancer	I-DS
compared	O
with	O
normal	O
tissue	O
.	O

MiR	O
-	O
101	O
ectopic	O
expression	O
in	O
epithelial	B-DS
ovarian	I-DS
cancer	I-DS
cell	O
lines	O
resulted	O
in	O
increased	O
apoptosis	O
,	O
decreased	O
cellular	O
proliferation	O
,	O
invasiveness	O
,	O
and	O
reduced	O
growth	O
of	O
tumor	B-DS
xenografts	O
[	O
28	O
,	O
29	O
].	O

Our	O
results	O
showed	O
that	O
miR	O
-	O
101	O
mimics	O
reduced	O
the	O
mRNA	O
and	O
protein	O
level	O
of	O
MARCH7	B-GP
in	O
ovarian	B-DS
cancer	I-DS
SKOV3	O
cells	O
.	O

We	O
further	O
confirmed	O
miR	O
-	O
101	O
inhibited	O
MARCH7	B-GP
expression	O
by	O
targeting	O
its	O
mRNA	O
3	O
′	O
UTR	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
confirms	O
that	O
MARCH7	B-GP
is	O
a	O
tumor	B-DS
promoting	O
gene	O
in	O
humans	B-OG
with	O
ovarian	B-DS
cancer	I-DS
,	O
which	O
was	O
involved	O
in	O
NFkB	B-GP
and	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
pathway	O
(	O
Fig	O
.	O

S2C	O
).	O

This	O
also	O
suggests	O
that	O
MARCH7	B-GP
may	O
be	O
a	O
potential	O
therapeutic	O
target	O
in	O
patients	O
with	O
epithelial	B-DS
ovarian	I-DS
cancer	I-DS
.	O

MATERIALS	O
AND	O
METHODS	O

Tissue	O
specimens	O

The	O
tissue	O
microarray	O
slides	O
containing	O
malignant	O
and	O
benign	O
ovarian	O
tissues	O
(	O
n	O
=	O
158	O
)	O
were	O
obtained	O
from	O
US	O
Biomax	O
Inc	O
cancer	B-DS
tissue	O
bank	O
collection	O
(	O
US	O
Biomax	O
Inc	O
.,	O
MD	O
,	O
USA	O
).	O

The	O
Ethics	O
Committee	O
of	O
the	O
Chongqing	O
Medical	O
University	O
approved	O
the	O
study	O
documents	O
and	O
the	O
use	O
of	O
archived	O
cancer	B-DS
tissues	O
.	O

All	O
patients	O
provided	O
a	O
written	O
informed	O
consent	O
.	O

Cell	O
culture	O
,	O
transfection	O
procedure	O
,	O
and	O
reagents	O

SKOV3	O
human	B-OG
ovarian	B-DS
cancer	I-DS
cell	O
line	O
derived	O
from	O
the	O
ascites	O
from	O
a	O
64	O
year	O
old	O
caucasian	O
female	O
with	O
an	O
ovarian	B-DS
tumor	I-DS
.	O

The	O
A2780	O
cell	O
line	O
was	O
established	O
from	O
tumor	B-DS
tissue	O
from	O
an	O
untreated	O
patient	O
.	O

The	O
ES	O
-	O
2	O
cell	O
line	O
was	O
established	O
from	O
a	O
surgical	O
tumor	B-DS
specimen	O
taken	O
from	O
a	O
47	O
year	O
old	O
black	O
woman	O
.	O

CAOV	O
-	O
3	O
human	B-OG
ovarian	B-DS
cancer	I-DS
cell	O
line	O
derived	O
from	O
a	O
54	O
years	O
old	O
caucasian	O
female	O
with	O
ovarian	B-DS
adenocarcinoma	I-DS
.	O

The	O
COC1	O
cell	O
line	O
was	O
derived	O
from	O
the	O
ascites	O
of	O
patients	O
with	O
poorly	O
differentiated	O
ovarian	B-DS
cancer	I-DS
.	O

Cisplatin	O
-	O
resistant	O
COC1	O
/	O
DDP	O
,	O
which	O
is	O
derived	O
from	O
its	O
parental	O
ovarian	B-DS
cancer	I-DS
cell	O
line	O
COC1	O
by	O
stepwise	O
selection	O
in	O
vitro	O
using	O
cisplatin	O
.	O

Human	B-OG
ovarian	B-DS
cancer	I-DS
cells	O
were	O
cultured	O
in	O
Rosewall	O
Park	O
Memorial	O
Institute	O
(	O
RPMI	O
)	O
1640	O
medium	O
,	O
containing	O
10	O
%	O
fetal	O
bovine	O
serum	O
and	O
antibiotics	O
,	O
and	O
incubated	O
in	O
an	O
atmosphere	O
with	O
5	O
%	O
carbon	O
dioxide	O
at	O
37	O
°	O
C	O
.	O

Double	O
-	O
strand	O
oligonucleotides	O
corresponding	O
to	O
the	O
target	O
sequences	O
were	O
synthesized	O
by	O
Genepharma	O
Co	O
.,	O
Ltd	O
.	O

(	O
Shanghai	O
,	O
China	O
).	O

The	O
following	O
sequences	O
were	O
targeted	O
for	O
human	B-OG
MARCH7	B-GP
,	O
NF	B-GP
-	I-GP
Kb	I-GP
p50	B-GP
,	O
and	O
NF	B-GP
-	I-GP
kB	I-GP
P65	B-GP
small	O
interfering	O
RNA	O
(	O
siRNA	O
),	O
respectively	O
.	O

MARCH7	B-GP
-	O
1	O
:	O
5	O
′-	O
GCACUUGGGAGUAAUUUGA	O
-	O
3	O
′;	O
MARCH7	B-GP
-	O
2	O
:	O
5	O
′-	O
GCACACGUGUCCGAUUUAU	O
-	O
3	O
′;	O
NF	B-GP
-	I-GP
Kb	I-GP
p50	B-GP
:	O
5	O
′-	O
GATTGAGGAGAAACGTAAA	O
-	O
3	O
′;	O
NF	B-GP
-	I-GP
Kb	I-GP
p65	B-GP
:	O
5	O
′-	O
GTCACTCTAACGTATGCAA	O
-	O
3	O
′	O
and	O
NC	O
(	O
negative	O
control	O
)	O
siRNA	O
:	O
5	O
′-	O
UUCUUCGAAGGUGUCACGUTT	O
-	O
3	O
′.	O

Lentiviral	O
vector	O
expressing	O
shRNA	O
targeting	O
MARCH7	B-GP
(	O
named	O
LV3	O
-	O
shMarch7	O
-	O
1	O
and	O
LV3	O
-	O
shMarch7	O
-	O
2	O
)	O
and	O
MARCH7	B-GP
-	O
lentiviral	O
expression	O
vector	O
(	O
named	O
LV5	O
-	O
March7	B-GP
)	O
were	O
provided	O
from	O
Genepharma	O
Co	O
.,	O
Ltd	O
.	O

(	O
Shanghai	O
,	O
China	O
).	O

miR	O
-	O
101	O
Mimics	O
(	O
sense	O
:	O
5	O
′-	O
UACAGUACUGUGAUAACUGAA	O
-	O
3	O
′)	O
were	O
synthesized	O
at	O
Ruibo	O
Biotech	O
(	O
Ruibo	O
Biotechnology	O
,	O
Guangzhou	O
,	O
China	O
).	O

Immunohistochemistry	O

Immunohistochemistry	O
(	O
IHC	O
)	O
was	O
performed	O
according	O
to	O
the	O
SP	O
kit	O
instructions	O
(	O
SP	O
-	O
9000	O
,	O
ZSGB	O
-	O
BIO	O
,	O
Beijing	O
,	O
China	O
).	O

After	O
dewaxing	O
and	O
hydration	O
,	O
the	O
sections	O
were	O
heated	O
in	O
citrate	O
buffer	O
(	O
pH	O
6	O
.	O
0	O
,	O
Sigma	O
-	O
Aldrich	O
,	O
USA	O
)	O
in	O
a	O
microwave	O
oven	O
for	O
20	O
minutes	O
for	O
antigen	O
retrieval	O
.	O

Further	O
,	O
the	O
sections	O
were	O
cooled	O
naturally	O
to	O
room	O
temperature	O
.	O

The	O
sections	O
were	O
washed	O
thrice	O
for	O
3	O
minutes	O
per	O
cycle	O
.	O

Subsequently	O
,	O
the	O
sections	O
were	O
incubated	O
in	O
3	O
%	O
aquae	O
hydrogenii	O
dioxidi	O
for	O
15	O
minutes	O
at	O
room	O
temperature	O
,	O
and	O
washed	O
thrice	O
with	O
phosphate	O
buffered	O
saline	O
(	O
PBS	O
)	O
for	O
3	O
minutes	O
per	O
cycles	O
.	O

The	O
sections	O
were	O
blocked	O
with	O
5	O
%	O
donkey	B-OG
serum	O
(	O
ab7475	O
Abcam	O
Company	O
)	O
for	O
30	O
minutes	O
at	O
37	O
°	O
C	O
.	O

Anti	O
-	O
MARCH7	B-GP
rabbit	B-OG
polyclonal	O
antibody	O
(	O
1	O
:	O
100	O
,	O
bs	O
-	O
9341R	O
,	O
Bioss	O
,	O
Beijing	O
,	O
China	O
)	O
was	O
incubated	O
with	O
the	O
sections	O
overnight	O
at	O
4	O
°	O
C	O
.	O

Negative	O
controls	O
included	O
omission	O
of	O
primary	O
antibody	O
and	O
use	O
of	O
irrelevant	O
primary	O
antibodies	O
.	O

The	O
corresponding	O
secondary	O
antibodies	O
that	O
were	O
conjugated	O
to	O
horseradish	B-OG
peroxidase	B-GP
(	O
Bioss	O
Biotechnology	O
)	O
were	O
incubated	O
with	O
the	O
sections	O
for	O
an	O
hour	O
at	O
room	O
temperature	O
.	O

The	O
sections	O
were	O
washed	O
thrice	O
in	O
PBS	O
for	O
3	O
minutes	O
per	O
cycle	O
.	O

The	O
sections	O
were	O
incubated	O
in	O
horseradish	B-OG
enzyme	O
-	O
labeled	O
chain	O
avidin	B-GP
solution	O
(	O
Bioss	O
Biotechnology	O
)	O
for	O
30	O
minutes	O
at	O
37	O
°	O
C	O
,	O
and	O
washed	O
in	O
PBS	O
for	O
3	O
minutes	O
x3	O
cycles	O
.	O

The	O
proteins	O
were	O
visualized	O
by	O
diaminobenzidine	O
.	O

All	O
the	O
sections	O
were	O
observed	O
by	O
3	O
independent	O
pathologists	O
using	O
a	O
light	O
microscope	O
.	O

The	O
staining	O
data	O
were	O
obtained	O
from	O
manually	O
recorded	O
reports	O
.	O

Staining	O
intensity	O
was	O
graded	O
on	O
a	O
0	O
–	O
3	O
scale	O
as	O
follows	O
:	O
0	O
(	O
absence	O
of	O
staining	O
),	O
1	O
(	O
weakly	O
stained	O
),	O
2	O
(	O
moderately	O
stained	O
),	O
and	O
3	O
(	O
strongly	O
stained	O
).	O

The	O
percentage	O
of	O
positive	O
tumor	B-DS
cells	O
was	O
scored	O
as	O
follows	O
:	O
0	O
(	O
absence	O
of	O
tumor	B-DS
cells	O
),	O
1	O
(<	O
33	O
%	O
tumor	B-DS
cells	O
),	O
2	O
(	O
33	O
–	O
66	O
%	O
tumor	B-DS
cells	O
)	O
and	O
3	O
(>	O
66	O
%	O
tumor	B-DS
cells	O
).	O

Immunohistochemical	O
score	O
(	O
ranging	O
from	O
0	O
to	O
9	O
)	O
was	O
calculated	O
by	O
multiplying	O
the	O
intensity	O
score	O
and	O
the	O
percentage	O
score	O
[	O
30	O
].	O

Quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O

Total	O
RNA	O
was	O
isolated	O
using	O
an	O
RNA	O
pure	O
High	O
-	O
purity	O
Total	O
RNA	O
Rapid	O
Extraction	O
Kit	O
(	O
BioTeke	O
,	O
RP1201	O
,	O
China	O
),	O
as	O
per	O
the	O
instructions	O
provided	O
in	O
the	O
kit	O
.	O

cDNA	O
was	O
synthesized	O
using	O
the	O
iSCRIPT	O
cDNA	O
synthesis	O
kit	O
(	O
Bio	O
-	O
Rad	O
).	O

The	O
primers	O
used	O
for	O
amplifying	O
MARCH7	B-GP
,	O
sp5	B-GP
,	O
lef1	B-GP
,	O
c	B-GP
-	I-GP
myc	I-GP
and	O
GAPDH	B-GP
were	O
synthesized	O
by	O
Guangzhou	O
Funeng	O
Co	O
.,	O
Ltd	O
.	O

The	O
real	O
-	O
time	O
PCR	O
kit	O
was	O
purchased	O
from	O
Guangzhou	O
Funeng	O
Co	O
.,	O
Ltd	O
.	O

PCR	O
conditions	O
were	O
95	O
°	O
C	O
for	O
10	O
seconds	O
,	O
60	O
°	O
C	O
for	O
20	O
seconds	O
,	O
72	O
°	O
C	O
for	O
10	O
seconds	O
.	O

Each	O
sample	O
was	O
analyzed	O
in	O
triplicates	O
.	O

Relative	O
quantification	O
of	O
mRNA	O
was	O
performed	O
using	O
the	O
comparative	O
threshold	O
cycles	O
(	O
CT	O
)	O
method	O
.	O

This	O
value	O
was	O
used	O
to	O
plot	O
the	O
gene	O
expression	O
employing	O
the	O
formula	O
2	O
−	O
Δ	O
ΔCT	O
.	O

Detection	O
of	O
protein	O
expression	O
by	O
Western	O
blotting	O

Expression	O
of	O
NF	B-GP
-	I-GP
kB	I-GP
p50	B-GP
,	O
P65	B-GP
,	O
MARCH7	B-GP
,	O
E	B-GP
-	I-GP
cadherin	I-GP
and	O
beta	B-GP
catenin	I-GP
protein	O
was	O
analyzed	O
by	O
the	O
Western	O
blot	O
method	O
[	O
9	O
].	O

The	O
primary	O
antibodies	O
used	O
included	O
polyclonal	O
rabbit	B-OG
anti	O
-	O
MARCH7	B-GP
(	O
1	O
:	O
1000	O
;	O
ab84130	O
;	O
Abcam	O
Inc	O
.,	O
Cambridge	O
,	O
MA	O
,	O
USA	O
);	O
polyclonal	O
rabbit	B-OG
anti	O
-	O
NF	B-GP
-	I-GP
kB	I-GP
p65	B-GP
(	O
1	O
:	O
1000	O
;	O
ab7970	O
;	O
Abcam	O
Inc	O
.,	O
Cambridge	O
,	O
MA	O
,	O
USA	O
);	O
polyclonal	O
rabbit	B-OG
anti	O
-	O
NF	B-GP
-	I-GP
kB	I-GP
p50	B-GP
(	O
1	O
:	O
1000	O
;	O
ab7971	O
;	O
Abcam	O
Inc	O
.,	O
Cambridge	O
,	O
MA	O
,	O
USA	O
);	O
anti	O
-	O
beta	B-GP
catenin	I-GP
antibody	O
rabbit	B-OG
polyclonal	O
antibody	O
(	O
1	O
:	O
500	O
,	O
bs	O
-	O
1165R	O
,	O
Bioss	O
,	O
Beijing	O
,	O
China	O
)	O
and	O
polyclonal	O
rabbit	B-OG
anti	O
-	O
GAPDH	B-GP
(	O
1	O
:	O
1000	O
;	O
AB10016	O
;	O
Sangon	O
Biotech	O
,	O
Shanghai	O
,	O
China	O
).	O

The	O
band	O
density	O
was	O
analyzed	O
using	O
a	O
gel	O
imaging	O
system	O
and	O
compared	O
against	O
an	O
internal	O
control	O
.	O

Cell	O
proliferation	O
assay	O

Cell	O
proliferation	O
was	O
determined	O
using	O
the	O
CCK	O
-	O
8	O
assay	O
as	O
described	O
previously	O
[	O
10	O
],	O
and	O
EdU	O
assay	O
was	O
performed	O
using	O
the	O
Cell	O
-	O
Light	O
TM	O
EdU	O
imaging	O
detecting	O
kit	O
according	O
to	O
the	O
instructions	O
in	O
the	O
kit	O
(	O
Ruibo	O
Biotechnology	O
,	O
Guangzhou	O
,	O
China	O
).	O

EdU	O
is	O
a	O
thymidine	O
analog	O
that	O
can	O
be	O
used	O
to	O
label	O
cells	O
undergoing	O
DNA	O
replication	O
[	O
11	O
].	O

Colony	O
formation	O
assay	O

SKOV3	O
cells	O
infected	O
with	O
LV3	O
-	O
shMarch7	O
-	O
1	O
or	O
LV3	O
-	O
shMarch7	O
-	O
2	O
,	O
and	O
A2780	O
cells	O
infected	O
with	O
LV5	O
-	O
March7	B-GP
were	O
cultured	O
by	O
seeding	O
1000	O
cells	O
in	O
6	O
-	O
well	O
plates	O
,	O
and	O
the	O
number	O
of	O
colonies	O
formed	O
was	O
checked	O
after	O
2	O
weeks	O
.	O

All	O
experiments	O
were	O
triplicated	O
.	O

Dual	O
-	O
luciferase	B-GP
reporter	O
gene	O
assay	O

Luciferase	B-GP
reporter	O
gene	O
assay	O
was	O
performed	O
using	O
the	O
Dual	O
-	O
Luciferase	B-GP
Reporter	O
Assay	O
System	O
(	O
Promega	O
)	O
according	O
to	O
the	O
instructions	O
provided	O
by	O
the	O
manufacturer	O
.	O

For	O
MARCH7	B-GP
3	O
′	O
UTR	O
luciferase	B-GP
reporter	O
assay	O
,	O
wild	O
type	O
or	O
mutant	O
reporter	O
constructs	O
(	O
termed	O
WT	O
or	O
Mut	O
;	O
purchased	O
from	O
Genepharma	O
Co	O
.,	O
Ltd	O
.,	O
Shanghai	O
,	O
China	O
)	O
were	O
co	O
-	O
transfected	O
into	O
skov3	O
cells	O
in	O
24	O
-	O
well	O
plates	O
with	O
100	O
nM	O
miR	O
-	O
101	O
or	O
100	O
nM	O
miR	O
-	O
NC	O
and	O
Renilla	B-OG
plasmid	O
by	O
using	O
Endofectin	O
™-	O
Plus	O
(	O
GeneCopoeia	O
).	O

TOPflash	O
reporter	O
plasmid	O
and	O
NF	B-GP
kB	I-GP
reporter	O
plasmids	O
were	O
purchased	O
from	O
Shanghai	O
Qcbio	O
Science	O
&	O
Technologies	O
Co	O
.,	O
Ltd	O
.	O

(	O
Shanghai	O
,	O
China	O
).	O

Reporter	O
gene	O
assay	O
was	O
performed	O
48	O
hours	O
post	O
-	O
transfection	O
using	O
the	O
Dual	O
Luciferase	B-GP
Assay	O
System	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
).	O

Firefly	B-OG
luciferase	B-GP
activity	O
was	O
normalized	O
for	O
transfection	O
efficiency	O
using	O
the	O
corresponding	O
Renilla	B-OG
luciferase	B-GP
activity	O
.	O

All	O
experiments	O
were	O
performed	O
at	O
least	O
3	O
times	O
.	O

Wound	O
healing	O
assay	O
and	O
Matrigel	O
invasion	O
assays	O

Migration	O
of	O
SKOV3	O
and	O
A2780	O
cells	O
were	O
analyzed	O
using	O
the	O
wound	O
-	O
healing	O
assay	O
in	O
vitro	O
.	O

Cells	O
were	O
seeded	O
into	O
6	O
-	O
well	O
plates	O
and	O
cultivated	O
until	O
90	O
%	O
growth	O
confluence	O
.	O

Wounds	O
were	O
afflicted	O
by	O
scraping	O
the	O
monolayer	O
cells	O
with	O
a	O
sterile	O
pipette	O
tip	O
.	O

At	O
0	O
,	O
24	O
,	O
48	O
and	O
72	O
hours	O
after	O
the	O
wounding	O
,	O
cells	O
were	O
observed	O
under	O
low	O
power	O
in	O
an	O
Olympus	O
light	O
microscope	O
.	O

The	O
distance	O
between	O
the	O
2	O
wounds	O
were	O
measured	O
at	O
each	O
time	O
point	O
,	O
and	O
expressed	O
as	O
the	O
average	O
percent	O
of	O
wound	O
closure	O
as	O
compared	O
to	O
that	O
at	O
zero	O
time	O
.	O

Invasion	O
of	O
SKOV3	O
and	O
A2780	O
cells	O
were	O
evaluated	O
by	O
Matrigel	O
invasion	O
assays	O
.	O

For	O
Transwell	O
invasion	O
assays	O
,	O
the	O
upper	O
side	O
of	O
an	O
8	O
μm	O
pore	O
,	O
6	O
.	O
5	O
-	O
mm	O
polycarbonate	O
transwell	O
filter	O
(	O
Corning	O
,	O
New	O
York	O
,	O
NY	O
)	O
chamber	O
was	O
uniformly	O
coated	O
with	O
Matrigel	O
basement	O
membrane	O
matrix	O
(	O
BD	O
Biosciences	O
,	O
Bedford	O
,	O
MA	O
)	O
for	O
2	O
h	O
at	O
37	O
°	O
C	O
before	O
the	O
cells	O
were	O
added	O
.	O

A	O
total	O
of	O
5	O
×	O
104	O
cells	O
were	O
seeded	O
into	O
the	O
top	O
chamber	O
of	O
a	O
trans	O
-	O
well	O
filter	O
(	O
in	O
triplicate	O
)	O
and	O
incubated	O
for	O
48	O
hours	O
.	O

Invasive	O
cells	O
on	O
the	O
lower	O
side	O
of	O
the	O
filter	O
,	O
were	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
,	O
stained	O
in	O
0	O
.	O
5	O
%	O
crystal	O
violet	O
(	O
Beyotime	O
),	O
and	O
counted	O
using	O
a	O
microscope	O
.	O

A	O
total	O
of	O
5	O
fields	O
were	O
counted	O
for	O
each	O
transwell	O
filter	O
.	O

Each	O
field	O
was	O
counted	O
and	O
photographed	O
at	O
200	O
×	O
magnification	O
.	O

In	O
vivo	O
tumor	B-DS
xenograft	O
study	O

All	O
procedures	O
for	O
animal	B-OG
experiments	O
were	O
approved	O
by	O
the	O
Committee	O
on	O
the	O
Use	O
and	O
Care	O
on	O
Animals	B-OG
(	O
Chongqing	O
Medical	O
University	O
,	O
Chongqing	O
,	O
China	O
),	O
and	O
performed	O
in	O
accordance	O
with	O
the	O
institution	O
guidelines	O
.	O

Ovarian	B-DS
cancer	I-DS
SKOV3	O
or	O
A2780	O
cells	O
were	O
infected	O
with	O
indicated	O
lentiviral	O
vectors	O
and	O
injected	O
(	O
5	O
×	O
106	O
cells	O
per	O
mouse	B-OG
in	O
200	O
ul	O
)	O
subcutaneously	O
into	O
the	O
left	O
armpit	O
of	O
6	O
-	O
week	O
-	O
old	O
BALB	B-OG
/	I-OG
c	I-OG
nude	I-OG
mice	I-OG
.	O

21	O
days	O
later	O
,	O
animals	B-OG
were	O
sacrificed	O
to	O
confirm	O
the	O
presence	O
of	O
tumors	B-DS
and	O
weigh	O
the	O
established	O
tumors	B-DS
.	O

Statistical	O
analysis	O

All	O
statistical	O
analyses	O
were	O
performed	O
using	O
SPSS	O
software	O
,	O
version	O
17	O
.	O
0	O
(	O
Chicago	O
,	O
IL	O
).	O

Each	O
experiment	O
was	O
performed	O
in	O
triplicates	O
.	O

Statistical	O
analysis	O
was	O
performed	O
by	O
Student	O
'	O
s	O
t	O
-	O
test	O
or	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
).	O

The	O
chi	O
-	O
square	O
test	O
was	O
used	O
to	O
compare	O
the	O
associations	O
between	O
MARCH7	B-GP
overexpression	O
and	O
clinicopathologic	O
variables	O
of	O
EOC	B-DS
samples	O
.	O

Data	O
were	O
presented	O
as	O
Mean	O
±	O
standard	O
deviation	O
.	O

Statistical	O
significance	O
was	O
defined	O
as	O
a	O
p	O
-	O
value	O
less	O
than	O
0	O
.	O
05	O
.	O

SUPPLEMENTARY	O
MATERIAL	O
,	O
FIGURES	O

Conflicts	O
of	O
Interest	O

There	O
are	O
no	O
potential	O
conflicts	O
of	O
interest	O
to	O
declare	O
.	O

